CTT Pharma Advances Micelle Thin-Film Technology Toward 2026 Production
TL;DR
CTT Pharma's patented micelle technology offers a competitive edge in drug delivery, with manufacturing plans for 2026 and SEC reporting to attract more investors.
CTT Pharma will file an S-1 for funding, use capital for manufacturing, hire regulatory experts, and locate a production facility in Q1 2026.
CTT Pharma's technology aims to improve oral drug delivery, potentially enhancing healthcare accessibility and offering a smoking cessation alternative through a Johns Hopkins partnership.
CTT Pharma's scientific paper on micelle strip technology will be published on December 15, 2025, increasing visibility and scientific understanding.
Found this article helpful?
Share it with your network and spread the knowledge!
CTT Pharma CEO Ryan Khouri detailed the company's strategy to move its patented micelle thin-film technology toward manufacturing and commercialization in a shareholder letter. The company plans to file an S-1 registration statement to access funding through an equity line and transition to an SEC reporting company, a step anticipated to enhance transparency and draw additional investors. Capital raised will be allocated to manufacturing oral dissolvable strip products, including micelle-encapsulated vitamins, bioactive supplements, and nicotine strips, with production targeted for 2026. Khouri stressed careful management of share count and dilution during this funding phase.
CTT Pharma is currently bolstering its team with regulatory specialists to navigate approval processes for North American sales and intends to hire more personnel with commercial product launch expertise. The company is also identifying a manufacturing facility in the first quarter, followed by equipment acquisition for production. A partnership with Johns Hopkins University continues under a National Institutes of Health grant investigating the technology as a smoking cessation alternative, though clinical trial funding is still pending. The company noted that its manufacturing and commercialization timeline is independent of this NIH decision.
The company recently reached a scientific milestone with the acceptance of a peer-reviewed manuscript for publication on December 15, 2025. The paper, co-authored by scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, offers a comprehensive review of micelle/oral dissolvable strip technology research. This publication is expected to boost visibility and understanding of the scientific principles behind CTT's platform among shareholders, potential partners, and the scientific community. Khouri also highlighted ongoing efforts to strengthen the company's patent portfolio and plans for a first-quarter conference call to discuss progress and upcoming initiatives. With capital becoming available, the company is expanding its team, advancing toward manufacturing, and defining regulatory pathways to bring its drug delivery technology to market.
Curated from NewMediaWire
